Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Comparison of Sildenafil ODF and FCT Formulations in Healthy Korean Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects were healthy male volunteers between the ages of 20 and 50 years and within 20% of their ideal body weight, and~* With no congenital abnormality or chronic disease.~Exclusion Criteria:~Key exclusion criteria included:~* history of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic, or hemorrhagic disease;~* anatomical abnormality of penis or factors that cause priapism (e.g., sicklemia, multiple myeloma, leukemia);~* clinically significant findings on routine laboratory (serology, hematology, serum chemistry, and urinalysis), ECG or color blindness tests \[8, 16\];~* history of hypersensitivity reaction to PDE5 inhibitor including sildenafil;~* use of prescription drugs within 14 days before the study that had the potential to interact with the study medication; and~* use of any substance that could induce or inhibit cytochrome P450 3A4 synthesis (eg, St. John's wort, other herbal medications).

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- SPO1101 (Type: EXPERIMENTAL): None
- SPO1101D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).